Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I single-ascending dose trial of APD 334 in volunteers.

Trial Profile

Phase I single-ascending dose trial of APD 334 in volunteers.

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2016

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Autoimmune disorders; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 30 Nov 2016 According to Arena Pharmaceuticals media release, data will be presented at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference.
    • 27 Feb 2014 Status changed from recruiting to completed, according to an Arena Pharmaceuticals media release.
    • 02 May 2013 Trial design is randomised, double-blind, placebo-controlled, according to an Arena media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top